Citius Pharmaceuticals (CTXR) Enterprise Value (2010 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Enterprise Value came in at $3.0 million in Q1 2026, up 2.18% YoY from $2.9 million in Q1 2025, and down 48.99% on a QoQ basis from $5.8 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Enterprise Value (2010 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 17 years of Enterprise Value data on file, last reported at $3.0 million in Q1 2026.
- Quarterly Enterprise Value rose 2.18% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (up 2.18% YoY) and the FY2025 annual result came in at $5.7 million, up 641.12% from the prior year.
- Enterprise Value slipped to $3.0 million in Q1 2026, from $5.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of $5.8 million in Q4 2025 to a low of -$55.2 million in Q1 2022.
- A 5-year average of -$17.6 million and a median of -$17.3 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2025 — Enterprise Value surged 641.12% — and 2026, when it rose 2.18%.
- Tracing CTXR's Enterprise Value over 5 years: stood at -$36.3 million in 2022, then jumped by 45.59% to -$19.7 million in 2023, then jumped by 112.21% to $2.4 million in 2024, then soared by 140.05% to $5.8 million in 2025, then sank by 48.99% to $3.0 million in 2026.
- The last three Enterprise Value figures came in at $3.0 million (Q1 2026), $5.8 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 2.12 Bn |
| 10 | Citius Pharmaceuticals | 15.97 Mn | 15.97 Mn | 1.00 Mn | -7.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.95 Mn |
| Dec 31, 2025 | 5.79 Mn |
| Sep 30, 2025 | 5.73 Mn |
| Jun 30, 2025 | -3.59 Mn |
| Mar 31, 2025 | 2.89 Mn |
| Dec 31, 2024 | 2.41 Mn |
| Sep 30, 2024 | 772,500.00 |
| Jun 30, 2024 | -17.31 Mn |
| Mar 31, 2024 | -11.96 Mn |
| Dec 31, 2023 | -19.75 Mn |
| Sep 30, 2023 | -25.88 Mn |
| Jun 30, 2023 | -32.68 Mn |
| Mar 31, 2023 | -28.47 Mn |
| Dec 31, 2022 | -36.29 Mn |
| Sep 30, 2022 | -41.11 Mn |
| Jun 30, 2022 | -47.44 Mn |
| Mar 31, 2022 | -55.16 Mn |
| Dec 31, 2021 | -64.82 Mn |
| Sep 30, 2021 | -69.47 Mn |
| Jun 30, 2021 | -115.06 Mn |